Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Supernus Pharmaceuticals (SUPN) stock
Learn how to easily invest in Supernus Pharmaceuticals stock.
Supernus Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Supernus Pharmaceuticals shares (SUPN) are listed on the NASDAQ and all prices are listed in US Dollars. Supernus Pharmaceuticals employs 563 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Supernus Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SUPN – and research it before deciding if it's a good investment for you.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Supernus Pharmaceuticals stock price (NASDAQ: SUPN)Use our graph to track the performance of SUPN stocks over time.
Supernus Pharmaceuticals shares at a glance
|Latest market close||$30.03|
|52-week range||$17.20 - $34.29|
|50-day moving average||$30.21|
|200-day moving average||$29.22|
|Wall St. target price||$35.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$2.07|
Buy Supernus Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Is it a good time to buy Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals price performance over time
|1 week (2021-07-15)||N/A|
|1 month (2021-06-25)||-8.05%|
|3 months (2021-04-26)||-5.83%|
|6 months (2021-01-22)||N/A|
|1 year (2020-07-22)||N/A|
|2 years (2019-07-22)||N/A|
|3 years (2018-07-22)||N/A|
|5 years (2016-07-22)||N/A|
Is Supernus Pharmaceuticals under- or over-valued?
Valuing Supernus Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Supernus Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Supernus Pharmaceuticals's P/E ratio
Supernus Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Supernus Pharmaceuticals shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Supernus Pharmaceuticals's PEG ratio
Supernus Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.47. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Supernus Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Supernus Pharmaceuticals's EBITDA
Supernus Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $196.3 million.
The EBITDA is a measure of a Supernus Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Supernus Pharmaceuticals financials
|Revenue TTM||$556.4 million|
|Operating margin TTM||31.15%|
|Gross profit TTM||$467.9 million|
|Return on assets TTM||8.03%|
|Return on equity TTM||16.25%|
|Market capitalisation||$1.4 billion|
TTM: trailing 12 months
Shorting Supernus Pharmaceuticals shares
There are currently 9.1 million Supernus Pharmaceuticals shares held short by investors – that's known as Supernus Pharmaceuticals's "short interest". This figure is 8.4% up from 8.4 million last month.
There are a few different ways that this level of interest in shorting Supernus Pharmaceuticals shares can be evaluated.
Supernus Pharmaceuticals's "short interest ratio" (SIR)
Supernus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Supernus Pharmaceuticals shares currently shorted divided by the average quantity of Supernus Pharmaceuticals shares traded daily (recently around 466654.08580184). Supernus Pharmaceuticals's SIR currently stands at 19.58. In other words for every 100,000 Supernus Pharmaceuticals shares traded daily on the market, roughly 19580 shares are currently held short.
However Supernus Pharmaceuticals's short interest can also be evaluated against the total number of Supernus Pharmaceuticals shares, or, against the total number of tradable Supernus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Supernus Pharmaceuticals's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 Supernus Pharmaceuticals shares in existence, roughly 170 shares are currently held short) or 0.1915% of the tradable shares (for every 100,000 tradable Supernus Pharmaceuticals shares, roughly 192 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Supernus Pharmaceuticals.
Find out more about how you can short Supernus Pharmaceuticals stock.
Supernus Pharmaceuticals share dividends
We're not expecting Supernus Pharmaceuticals to pay a dividend over the next 12 months.
Supernus Pharmaceuticals share price volatility
Over the last 12 months, Supernus Pharmaceuticals's shares have ranged in value from as little as $17.2 up to $34.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Supernus Pharmaceuticals's is 1.2541. This would suggest that Supernus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Supernus Pharmaceuticals overview
Supernus Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc.
Stocks similar to Supernus Pharmaceuticals
Supernus Pharmaceuticals in the news
Absolute Investment Management Llc Buys iShares Core S&P Mid-Cap ETF, ProShares Russell 2000 Div Growers ETF, Vanguard Consumer Discretionary ETF, Sells iShares Gold Trust, PIMCO Enhanced Short Maturity Active Exchange-Trad, ProShares S&P 500 Dividend Ari
Supernus to Host Second Quarter 2021 Financial Results Conference Call
Supernus to Host Second Quarter 2021 Financial Results Conference Call
Frequently asked questionsWhat percentage of Supernus Pharmaceuticals is owned by insiders or institutions?
Currently 3.555% of Supernus Pharmaceuticals shares are held by insiders and 104.81% by institutions. How many people work for Supernus Pharmaceuticals?
Latest data suggests 563 work at Supernus Pharmaceuticals. When does the fiscal year end for Supernus Pharmaceuticals?
Supernus Pharmaceuticals's fiscal year ends in December. Where is Supernus Pharmaceuticals based?
Supernus Pharmaceuticals's address is: 9715 Key West Avenue, Rockville, MD, United States, 20850 What is Supernus Pharmaceuticals's ISIN number?
Supernus Pharmaceuticals's international securities identification number is: US8684591089 What is Supernus Pharmaceuticals's CUSIP number?
Supernus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 868459108
More guides on Finder
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
Ask an Expert